Liraglutide, a glucagon-like peptide-1 (GLP-1) agonist with, presently, the most promising weight-lowering effect, increases incidence of symptomatic gallstones and may elevate the risk of pancreatitis apart from gastrointestinal symptoms (Pi-Sunyer et al., 2015). This evidence concerns the gene GCG and gallstones.